Contract for procurement of Mogamulizumab 20 mg in 5mL concentrate for solution for infusion

GoodsAward procedure without prior publication of a call for competition

Awarded value£150,000published contract · exc. VAT

Awarded 1 Apr 2023no call for competition

Awarded to Alloga UK

What is being bought

Published requirement description

Contract for procurement of Mogamulizumab 20 mg in 5mL concentrate for solution for infusion for three years

CPV: Pharmaceutical products

single lot · no lot value published

Lot #1Awarded

Delivery: Northern Ireland

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 30 Aug 2023, 11:27 BST
Last source update: 30 Aug 2023, 11:27 BST
Authority reference: DAC32/0623PM
FTS notice number: 2023/S 000-025423
Classification (CPV): Pharmaceutical products
Delivery area: Northern Ireland (UKN)
Official registry OCID: ocds-h6vhtk-03f7ea Find a Tender

Why no open competition: The works, supplies or services can be provided only by a particular economic operator due to protection of exclusive rights, including intellectual property rights
Published justification: Regulation 32(2)(b)iii permits the award of a public contract by a negotiated procedure without prior publication where the works, supplies or services can only be supplied by a particular economic operator due to the protection of exclusive rights, including intellectual property rights. The absence of competition is not the result of an artificial narrowing down of the parameters of the procurement.
The Northern Trust requires the purchase of MOGAMULIZUMAB which is subject to patent protection / Sole MA Holder and consequently no reasonable alternative of substitute exists.

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £150,0001 contract exc. VAT

Bids received 1

Contracts signed 1latest 1 Apr 2023

Awarded to	Value	Date	Status
Alloga UKProcurement of Mogamulizumab 20 mg in 5mL concentrate for solution for infusion	£150,000 †	—	Awarded

Contracts

Procurement of Mogamulizumab 20 mg in 5mL concentrate for solution for infusion · Alloga UK
Signed
1 Apr 2023
Value
£150,000
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

Contracting authorityCentral GovernmentBody governed by public lawHealth Bush Road, Antrim, Northern Ireland, BT41 2RLContact name, email, phone

1 commercial party on the notice

ALLOGA UK LTDAwarded supplierGB-COH: 03169255 Amber Park, Berristow Lane, Alfreton, East Midlands, DE55 2FH

Official links; attachments are not copied

No document links were published on the notice.